NO117982B - - Google Patents
Download PDFInfo
- Publication number
- NO117982B NO117982B NO65159024A NO15902465A NO117982B NO 117982 B NO117982 B NO 117982B NO 65159024 A NO65159024 A NO 65159024A NO 15902465 A NO15902465 A NO 15902465A NO 117982 B NO117982 B NO 117982B
- Authority
- NO
- Norway
- Prior art keywords
- acid
- naphthyl
- mol
- ester
- product
- Prior art date
Links
- 239000002253 acid Substances 0.000 claims description 28
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 9
- 150000007513 acids Chemical class 0.000 claims description 8
- 230000000304 vasodilatating effect Effects 0.000 claims description 8
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 7
- 230000002921 anti-spasmodic effect Effects 0.000 claims description 6
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims description 5
- 150000003891 oxalate salts Chemical class 0.000 claims description 5
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 3
- 239000000812 cholinergic antagonist Substances 0.000 claims description 3
- 239000001530 fumaric acid Substances 0.000 claims description 3
- 235000006408 oxalic acid Nutrition 0.000 claims description 3
- 239000012458 free base Substances 0.000 claims description 2
- 230000003472 neutralizing effect Effects 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- 239000000047 product Substances 0.000 description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 235000019441 ethanol Nutrition 0.000 description 12
- -1 tetrahydrofurfuryl radical Chemical class 0.000 description 12
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- 239000013078 crystal Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000002844 melting Methods 0.000 description 8
- 230000008018 melting Effects 0.000 description 8
- 239000002585 base Substances 0.000 description 7
- 238000009835 boiling Methods 0.000 description 7
- 238000001953 recrystallisation Methods 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000004821 distillation Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- GEVPUGOOGXGPIO-UHFFFAOYSA-N oxalic acid;dihydrate Chemical compound O.O.OC(=O)C(O)=O GEVPUGOOGXGPIO-UHFFFAOYSA-N 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000032050 esterification Effects 0.000 description 3
- 238000005886 esterification reaction Methods 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000003589 local anesthetic agent Substances 0.000 description 2
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 208000003782 Raynaud disease Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- 229960001413 acetanilide Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- UYMKPFRHYYNDTL-UHFFFAOYSA-N ethenamine Chemical class NC=C UYMKPFRHYYNDTL-UHFFFAOYSA-N 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000030175 lameness Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960001789 papaverine Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR929519A FR1363948A (fr) | 1963-03-28 | 1963-03-28 | Nouvelles bases azotées substituées par au moins un radical naphtyle ou naphtylméthyle |
Publications (1)
Publication Number | Publication Date |
---|---|
NO117982B true NO117982B (ja) | 1969-10-20 |
Family
ID=8800292
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO65159024A NO117982B (ja) | 1963-03-28 | 1965-07-20 |
Country Status (13)
Country | Link |
---|---|
US (1) | US3334096A (ja) |
AT (2) | AT247309B (ja) |
BE (1) | BE645366A (ja) |
BR (1) | BR6457920D0 (ja) |
CH (1) | CH483395A (ja) |
DE (2) | DE1493920C3 (ja) |
DK (2) | DK125702B (ja) |
ES (1) | ES298057A1 (ja) |
FR (1) | FR1363948A (ja) |
GB (3) | GB1022034A (ja) |
NL (5) | NL142872B (ja) |
NO (1) | NO117982B (ja) |
SE (2) | SE335351B (ja) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3458529A (en) * | 1964-06-10 | 1969-07-29 | Lipha | Nitrogenous bases substituted by at least one naphthyl or naphthylmethyl radical |
FR5671M (ja) * | 1965-04-23 | 1968-01-02 | ||
US3896157A (en) * | 1967-01-13 | 1975-07-22 | Syntex Corp | Dihydo 2-naphthylacetic acid derivatives |
US4048330A (en) * | 1967-01-13 | 1977-09-13 | Syntex Corporation | Compositions containing 2-(6'-substituted-2'-naphthyl)acetic acid esters used for treating inflammation, pain or pyrexia |
US3973033A (en) * | 1971-07-29 | 1976-08-03 | Lipha, Lyonnaise Industrielle Pharmaceutique | Compositions and methods for producing a vasodilatory effect with a naphthyl tetrahydrofurfuryl amino-ester |
FR2146981B1 (ja) * | 1971-07-29 | 1974-09-06 | Lipha | |
US3975390A (en) * | 1973-07-26 | 1976-08-17 | Richter Gedeon Vegyeszeti Gyar Rt. | N-methyl substituted piperazino nitrobenzophenones and a process for the preparation thereof |
FR2371197A1 (fr) * | 1976-11-18 | 1978-06-16 | Bottu | Nouveaux derives de l'acide isobutyrique disubstitue ainsi que leur application comme medicaments |
FR2377196A1 (fr) * | 1977-01-13 | 1978-08-11 | Lipha | Composition medicamenteuse a usage oral |
HU177876B (en) * | 1979-04-24 | 1982-01-28 | Nitrokemia Ipartelepek | Process for preparing 2,6-dialkyl-n-/alkoxy-methyl/-chloro-acetanilide derivatives |
FR2505836A1 (fr) * | 1981-05-14 | 1982-11-19 | Sanofi Sa | Citrate de naftidrofuryl et son application therapeutique |
FR2580502B1 (fr) * | 1985-04-23 | 1988-07-08 | Lipha | Emploi du " naftidrofuryl " dans la preparation d'un medicament |
JPH0662521B2 (ja) * | 1988-02-24 | 1994-08-17 | 日東紡績株式会社 | 新規コリン誘導体及びそれを用いた血清コリンエステラーゼ活性測定法 |
ATE502635T1 (de) | 2002-08-19 | 2011-04-15 | Pfizer | Kombinationstherapie gegen hyperproliferative erkrankungen |
US20050037063A1 (en) * | 2003-07-21 | 2005-02-17 | Bolton Anthony E. | Combined therapies |
US20060063803A1 (en) * | 2004-09-23 | 2006-03-23 | Pfizer Inc | 4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds |
US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
JP5498168B2 (ja) | 2006-12-01 | 2014-05-21 | ブリストル−マイヤーズ スクイブ カンパニー | アテローム性動脈硬化および循環器疾患の治療のためのcetp阻害剤としてのn−((3−ベンジル)−2,2−(ビス−フェニル)−プロパン−1−アミン誘導体 |
JP2016516804A (ja) | 2013-04-17 | 2016-06-09 | ファイザー・インク | 心血管疾患を治療するためのn−ピペリジン−3−イルベンズアミド誘導体 |
WO2016055901A1 (en) | 2014-10-08 | 2016-04-14 | Pfizer Inc. | Substituted amide compounds |
JP7128969B2 (ja) | 2019-01-18 | 2022-08-31 | アストラゼネカ・アクチエボラーグ | Pcsk9阻害剤及びその使用方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2417208A (en) * | 1943-08-04 | 1947-03-11 | Geigy Ag J R | Basic esters of monoalkyl isobutyl acetic acids |
CH396872A (de) * | 1959-08-13 | 1965-08-15 | Ciba Geigy | Verfahren zur Herstellung neuer Harnstoffe |
US3242174A (en) * | 1962-02-06 | 1966-03-22 | Pfizer & Co C | 1-(tertiary aminosulfonyl)-3-(hydrocarbon) ureas |
-
0
- NL NL142872D patent/NL142872C/xx active
-
1963
- 1963-03-28 FR FR929519A patent/FR1363948A/fr not_active Expired
-
1964
- 1964-03-16 SE SE11642/66A patent/SE335351B/xx unknown
- 1964-03-16 SE SE3234/64A patent/SE306747B/xx unknown
- 1964-03-18 BE BE645366D patent/BE645366A/xx unknown
- 1964-03-18 US US352963A patent/US3334096A/en not_active Expired - Lifetime
- 1964-03-23 GB GB32352/65A patent/GB1022034A/en not_active Expired
- 1964-03-23 GB GB12259/64A patent/GB1022032A/en not_active Expired
- 1964-03-23 GB GB32350/65A patent/GB1022033A/en not_active Expired
- 1964-03-24 DE DE1493920A patent/DE1493920C3/de not_active Expired
- 1964-03-24 DE DE1543741A patent/DE1543741C3/de not_active Expired
- 1964-03-25 AT AT778864A patent/AT247309B/de active
- 1964-03-25 CH CH394364A patent/CH483395A/fr not_active IP Right Cessation
- 1964-03-25 AT AT260964A patent/AT250339B/de active
- 1964-03-25 BR BR157920/64A patent/BR6457920D0/pt unknown
- 1964-03-25 DK DK152064AA patent/DK125702B/da unknown
- 1964-03-26 NL NL646403315A patent/NL142872B/xx not_active IP Right Cessation
- 1964-03-26 ES ES298057A patent/ES298057A1/es not_active Expired
-
1965
- 1965-07-20 NO NO65159024A patent/NO117982B/no unknown
-
1966
- 1966-06-24 DK DK325466AA patent/DK118773B/da unknown
-
1974
- 1974-01-22 NL NL7400839A patent/NL7400839A/xx unknown
- 1974-01-22 NL NL7400837A patent/NL7400837A/xx unknown
- 1974-01-22 NL NL7400838A patent/NL7400838A/xx unknown
Also Published As
Publication number | Publication date |
---|---|
ES298057A1 (es) | 1964-06-01 |
FR1363948A (fr) | 1964-06-19 |
AT247309B (de) | 1966-06-10 |
NL7400839A (ja) | 1974-04-25 |
US3334096A (en) | 1967-08-01 |
DE1543741A1 (de) | 1969-12-11 |
SE335351B (ja) | 1971-05-24 |
NL7400837A (ja) | 1974-04-25 |
DE1493920C3 (de) | 1974-01-17 |
SE306747B (ja) | 1968-12-09 |
GB1022032A (en) | 1966-03-09 |
DE1543741C3 (de) | 1974-02-07 |
CH483395A (fr) | 1969-12-31 |
BE645366A (ja) | 1964-09-18 |
NL6403315A (ja) | 1964-09-29 |
DK125702B (da) | 1973-03-26 |
GB1022034A (en) | 1966-03-09 |
NL142872C (ja) | |
DE1493920B2 (de) | 1973-06-20 |
GB1022033A (en) | 1966-03-09 |
BR6457920D0 (pt) | 1973-02-22 |
NL7400838A (ja) | 1974-04-25 |
DK118773B (da) | 1970-10-05 |
DE1543741B2 (de) | 1973-07-05 |
AT250339B (de) | 1966-11-10 |
DE1493920A1 (de) | 1969-07-10 |
NL142872B (nl) | 1974-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO159024B (no) | Fremgangsmaate for fremstilling av butanol fra sukker. | |
NO117982B (ja) | ||
Burke | 3, 4-Dihydro-1, 3, 2H-Benzoxazines. Reaction of p-substituted phenols with N, N-dimethylolamines | |
NO123804B (ja) | ||
Blicke et al. | LOCAL ANESTHETICS IN THE PYRROLE SERIES. I1, 2 | |
NO150734B (no) | Fremgangsmaate ved produksjon av olje eller gass gjennom en broenn som strekker seg gjennom en olje- eller gassholdig formasjon | |
US2918407A (en) | Anti-spasmodics specific for upper gastrointestinal pain and spasm | |
US2625567A (en) | 1-benzyloxy-2-alkylaminoindanes | |
Cornforth et al. | 218. Mechanism and extension of the Fischer oxazole synthesis | |
US3325515A (en) | Coumarin derivatives and their preparation | |
Wilkinson et al. | The biological action of substances related to thyroxine. 4. The thyroxine-inhibitory properties of a series of 4-hydroxy-3: 5-diiodobenzoates of glycols | |
Julian et al. | The Constituents of Ceanothus Americanus. I. Ceanothic Acid1 | |
Browning et al. | The trypanocidal action of some derivatives of anil and styryl quinolines.—II | |
US3244729A (en) | Dimethoxy-x-methyl-g,y-furanocou- marin compounds | |
US2921077A (en) | 2-methyl-6-carbalkoxy-n-alkylaminoacylanilides | |
US3532704A (en) | Anesthetic butoxydimethylbenzamides | |
NO128798B (ja) | ||
US3347858A (en) | Tertiary aminoethyl | |
US3317526A (en) | Omega-tertiaryamino butynol-1-phenylcycloalkane carboxylates | |
US4060637A (en) | Medicaments having psychotropic properties | |
US3094463A (en) | Composition consisting of 2-pyrrolidylmethyl-nu-lower alkyl and 3-piperidyl-nu-lower alkyl phenylglycolates as anti spasmodics and central stimulant, and process of preparation | |
Weizmann | Side Reaction in the Hydrogenation of 4-Nitro-2-chlorobenzoic Acid and Its Esters | |
US3940490A (en) | Medicaments having psychotropic properties | |
US3458507A (en) | 3-tropanyl-2-aminophenylacrylate compounds | |
DE586247C (de) | Verfahren zur Gewinnung von basischen Estern fettaromatischer Saeuren |